A new risk assessment score developed by researchers at Dana-Farber Cancer Institute, the Broad Institute of MIT and Harvard, and Massachusetts General Hospital reveals how multiple myeloma, a form of ...

Agency drug reviewers had questioned patient risk criteria and the efficacy endpoint used in a key trial supporting J&J's ...

A new risk assessment score developed by researchers at Dana-Farber Cancer Institute and the Broad Institute of MIT and Harvard reveals how multiple myeloma, a form of blood cancer, begins and ...

A new risk assessment score developed by researchers at Dana-Farber Cancer Institute and the Broad Institute of MIT and ...

Farber Cancer Institute and the Broad Institute of MIT and Harvard reveals how multiple myeloma, a form of blood cancer, begins and progresses from precancerous to malignant states by tracing DNA ...

A new risk assessment score developed by researchers at Dana-Farber Cancer Institute and the Broad Institute of MIT and ...

To mark World Blood Cancer Day tomorrow, we’re remembering how we’ve been affected by the type of cancer and our efforts to ...

CAR T-cell therapy involves extracting a patient’s own immune cells, reprogramming them to recognise and destroy cancer cells ...

Adding Blenrep to standard therapy prolonged progression-free survival in patients with relapsed or refractory multiple ...

Johnson & Johnson has won the support of an FDA expert panel in its bid to make Darzalex the first treatment for an early ...

GSK (GSK) stock in focus as its antibody drug conjugate Blenrep gains EMA recommendation for relapsed multiple myeloma with ...